Assessment of hepatitis c core antigen in epithelial salivary gland neoplasms (ex-vivo study).
HCV core antigen
Hepatitis C
Immunohistochemistry
Salivary gland neoplasms
Journal
BMC oral health
ISSN: 1472-6831
Titre abrégé: BMC Oral Health
Pays: England
ID NLM: 101088684
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
18
05
2024
accepted:
18
07
2024
medline:
7
8
2024
pubmed:
7
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
Salivary gland neoplasms (SGNs) pose a challenge to both pathologists and clinicians. Despite research, the etiology of these neoplasms remains unclear. This study aimed to identify any potential association between the presence of hepatitis C virus (HCV) at the protein or gene level and epithelial salivary gland neoplasms. Formalin-fixed paraffin-embedded (FFPE) blocks of epithelial salivary gland neoplasms were retrieved from the archives of the Oral and Maxillofacial Pathology Department, Faculty of Dentistry, Cairo University within the 5-year period from 2016 to 2020. Immunohistochemistry was used to assess HCV core antigen, while reverse transcription polymerase chain reaction was employed for the evaluation of HCV RNA. A total of 44 specimens were collected, 28 of which were benign neoplasms and 16 were malignant neoplasms. There was a statistically significant difference in HCV positivity between the two groups (P-value = 0.036). Benign tumors showed a statistically significant lower percentage of positive cases than malignant tumors. The localization of staining was also evaluated, revealing various patterns of HCV core antigen expression, including diffuse cytoplasmic, patchy cytoplasmic, nuclear, and a combination of nuclear and cytoplasmic expression. There was no statistically significant difference between the expression patterns in benign and malignant tumors (P-value = 0.616). Given that Pleomorphic Adenoma and Mucoepidermoid Carcinoma were the predominant tumor types in this study, four cases were selected for RNA detection. HCV RNA was detected in all cases using RT-PCR. HCV core antigen is frequently detected in SGNs and is suggested to be a potential risk factor for the development of these neoplasms. Further studies are required to discover other biomarkers, their roles, and the pathways associated with HCV in SGNs.
Sections du résumé
BACKGROUND
BACKGROUND
Salivary gland neoplasms (SGNs) pose a challenge to both pathologists and clinicians. Despite research, the etiology of these neoplasms remains unclear. This study aimed to identify any potential association between the presence of hepatitis C virus (HCV) at the protein or gene level and epithelial salivary gland neoplasms.
METHODS
METHODS
Formalin-fixed paraffin-embedded (FFPE) blocks of epithelial salivary gland neoplasms were retrieved from the archives of the Oral and Maxillofacial Pathology Department, Faculty of Dentistry, Cairo University within the 5-year period from 2016 to 2020. Immunohistochemistry was used to assess HCV core antigen, while reverse transcription polymerase chain reaction was employed for the evaluation of HCV RNA.
RESULTS
RESULTS
A total of 44 specimens were collected, 28 of which were benign neoplasms and 16 were malignant neoplasms. There was a statistically significant difference in HCV positivity between the two groups (P-value = 0.036). Benign tumors showed a statistically significant lower percentage of positive cases than malignant tumors. The localization of staining was also evaluated, revealing various patterns of HCV core antigen expression, including diffuse cytoplasmic, patchy cytoplasmic, nuclear, and a combination of nuclear and cytoplasmic expression. There was no statistically significant difference between the expression patterns in benign and malignant tumors (P-value = 0.616). Given that Pleomorphic Adenoma and Mucoepidermoid Carcinoma were the predominant tumor types in this study, four cases were selected for RNA detection. HCV RNA was detected in all cases using RT-PCR.
CONCLUSIONS
CONCLUSIONS
HCV core antigen is frequently detected in SGNs and is suggested to be a potential risk factor for the development of these neoplasms. Further studies are required to discover other biomarkers, their roles, and the pathways associated with HCV in SGNs.
Identifiants
pubmed: 39107729
doi: 10.1186/s12903-024-04632-9
pii: 10.1186/s12903-024-04632-9
doi:
Substances chimiques
Hepatitis C Antigens
0
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
900Informations de copyright
© 2024. The Author(s).
Références
Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74(2):134–48.
doi: 10.1016/j.critrevonc.2009.10.004
pubmed: 19939701
Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res. 2011;157(2):193–203.
doi: 10.1016/j.virusres.2010.10.026
pubmed: 21036194
Carrozzo M, Gandolfo S. Oral diseases possibly associated with hepatitis C virus. Crit Rev Oral Biol Med. 2003;14(2):115–27.
doi: 10.1177/154411130301400205
pubmed: 12764074
Hassanin A, Kamel S, Waked I, Fort M. Egypt’s ambitious strategy to eliminate hepatitis C virus: a case study. Glob Health Sci Pract. 2021;9(1):187–200.
doi: 10.9745/GHSP-D-20-00234
pubmed: 33795369
pmcid: 8087425
Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet. 2000;355(9207):887–91.
doi: 10.1016/S0140-6736(99)06527-7
pubmed: 10752705
El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15(12):1643–52.
doi: 10.1080/14740338.2017.1240781
pubmed: 27661100
Metwally AM, Elmosalami DM, Elhariri H, El Etreby LA, Aboulghate A, El-Sonbaty MM, et al. Accelerating Hepatitis C virus elimination in Egypt by 2030: a national survey of communication for behavioral development as a modelling study. PLoS One. 2021;16(2):e0242257.
doi: 10.1371/journal.pone.0242257
pubmed: 33621232
pmcid: 7901784
Grossmann Sde M, Teixeira R, Oliveira GC, Gleber-Netto FO, Araújo FM, Carmo MA. Xerostomia, hyposalivation and sialadenitis in patients with chronic hepatitis C are not associated with the detection of HCV RNA in saliva or salivary glands. J Clin Pathol. 2010;63(11):1002–7.
doi: 10.1136/jcp.2010.080036
pubmed: 20924089
Rangel JB, Thuler LCS, Pinto J. Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients. Oral Oncol. 2018;87:138–43.
doi: 10.1016/j.oraloncology.2018.10.024
pubmed: 30527229
Yi Z, Yuan Z. Hepatitis C virus-associated cancers. Adv Exp Med Biol. 2017;1018:129–46.
doi: 10.1007/978-981-10-5765-6_8
pubmed: 29052135
Balakrishnan M, Glover MT, Kanwal F. Hepatitis C and risk of non-hepatic malignancies. Clin Liver Dis. 2017;21(3):543–54.
doi: 10.1016/j.cld.2017.03.009
pubmed: 28689592
Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ, Torres HA. association between hepatitis C virus and head and neck cancers. J Natl Cancer Inst. 2016;108(8):djw035.
doi: 10.1093/jnci/djw035
pubmed: 27075854
pmcid: 5017939
Nawito Z, Amin A, El-Fadl SA, Abu El Einen K. Sicca complex among Egyptian patients with chronic hepatitis C virus infection. Clin Rheumatol. 2011;30(10):1299–304.
doi: 10.1007/s10067-011-1746-x
pubmed: 21487733
Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis. 2013;13:288.
doi: 10.1186/1471-2334-13-288
pubmed: 23799878
pmcid: 3702438
Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1):3–14.
pubmed: 26862398
pmcid: 4735500
Carrozzo M. Oral diseases associated with hepatitis C virus infection. Part 1. sialadenitis and salivary glands lymphoma. Oral Dis. 2008;14(2):123–30.
doi: 10.1111/j.1601-0825.2007.01436.x
pubmed: 18208477
Chen AA, Gheit T, Stellin M, Lupato V, Spinato G, Fuson R, et al. Oncogenic DNA viruses found in salivary gland tumors. Oral Oncol. 2017;75:106–10.
doi: 10.1016/j.oraloncology.2017.11.005
pubmed: 29224806
Lin HH, Limesand KH, Ann DK. Current State of knowledge on salivary gland cancers. Crit Rev Oncog. 2018;23(3–4):139–51.
doi: 10.1615/CritRevOncog.2018027598
pubmed: 30311570
pmcid: 6415949
Porcheri C, Meisel CT, Mitsiadis TA. Molecular and cellular modelling of salivary gland tumors open new landscapes in diagnosis and treatment. Cancers (Basel). 2020;12(11):3107.
doi: 10.3390/cancers12113107
pubmed: 33114321
pmcid: 7690880
Pessôa MG, Alves VA, Wakamatsu A, Gomes JG, Maertens G, van der Borght B, et al. Post-transplant recurrent hepatitis C: immunohistochemical detection of hepatitis C virus core antigen and possible pathogenic implications. Liver Int. 2008;28(6):807–13.
doi: 10.1111/j.1478-3231.2008.01739.x
pubmed: 18422936
Ranka R, Chaudhary M, Patil S, Gawande M, Jain A, Sharma P, et al. Prevalence of hepatitis C virus infection in potentially malignant disorders and oral squamous cell carcinoma-an immunohistochemical study. Hos Pal Med Int J. 2018;2(6):398–403.
Kamal N, Dahmoush H, Waguih H, Helmy E. Hepatitis C virus detection in oral squamous cell Carcinoma. Indian J Public Health Res Dev. 2021;12(1):352–61.
Shiha GE, Zalata KR, Abdalla AF, Mohamed MK. Immunohistochemical identification of HCV target antigen in paraffin-embedded liver tissue: reproducibility and staining patterns. Liver Int. 2005;25(2):254–60.
doi: 10.1111/j.1478-3231.2005.01101.x
pubmed: 15780047
Suzuki R, Sakamoto S, Tsutsumi T, Rikimaru A, Tanaka K, Shimoike T, et al. Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol. 2005;79(2):1271–81.
doi: 10.1128/JVI.79.2.1271-1281.2005
pubmed: 15613354
pmcid: 538550
Machida K, Tsukiyama-Kohara K, Seike E, Toné S, Shibasaki F, Shimizu M, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem. 2001;276(15):12140–6.
doi: 10.1074/jbc.M010137200
pubmed: 11278624
Cerutti A, Maillard P, Minisini R, Vidalain PO, Roohvand F, Pecheur EI, et al. Identification of a functional, CRM-1-dependent nuclear export signal in hepatitis C virus core protein. PLoS One. 2011;6(10):e25854.
doi: 10.1371/journal.pone.0025854
pubmed: 22039426
pmcid: 3200325
Rullier A, Trimoulet P, Urbaniak R, Winnock M, Zauli D, Ballardini G, et al. Immunohistochemical detection of hcv in cirrhosis, dysplastic nodules, and hepatocellular carcinomas with parallel-tissue quantitative RT-PCR. Mod Pathol. 2001;14(5):496–505.
doi: 10.1038/modpathol.3880338
pubmed: 11353061
Zheng A, Yuan F, Li Y, Zhu F, Hou P, Li J, et al. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J Virol. 2007;81(22):12465–71.
doi: 10.1128/JVI.01457-07
pubmed: 17804490
pmcid: 2169001
Baker OJ. Current trends in salivary gland tight junctions. Tissue Barriers. 2016;4(3):e1162348.
doi: 10.1080/21688370.2016.1162348
pubmed: 27583188
pmcid: 4993573
Arruda CFJ, Coutinho-Camillo CM, Marques MM, Nagano CP, Bologna SB, Bettim BB, et al. Claudin expression is maintained in mucoepidermoid carcinoma of the salivary gland. Pathol Res Pract. 2020;216(11):153161.
doi: 10.1016/j.prp.2020.153161
pubmed: 32862070
Taliani G, Celestino D, Badolato MC, Pennica A, Bozza A, Poliandri G, et al. Hepatitis C virus infection of salivary gland epithelial cells. Lack Evid J Hepatol. 1997;26(6):1200–6.
doi: 10.1016/S0168-8278(97)80452-7